The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers

Pascale A Cohen; Olivier Loudig; Christina Liu; Joseph Albanese; Susan Fineberg

doi:10.3389/fphar.2019.00524

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX^® Recurrence Score in ER-Positive Invasive Breast Cancers

Front Pharmacol. 2019 May 28:10:524. doi: 10.3389/fphar.2019.00524. eCollection 2019.

Authors

Pascale A Cohen^{1

2}, Olivier Loudig³, Christina Liu³, Joseph Albanese⁴, Susan Fineberg⁴

Affiliations

¹ Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
² Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, United States.
³ Center for Discovery and Innovation, Hackensack University Medical Center (HUMC), Nutley, NJ, United States.
⁴ Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, United States.

Abstract

We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX^® Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX^® Recurrence Score.

Keywords: Oncotype DX®; ZNF217; biomarker; breast cancer; estrogen-receptor positive; expression.